http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 24 Jul 2026 07:31:28 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Curis+%28CRIS%29+PT+Raised+to+%2443+at+H.C.+Wainwright/26810687.html H.C. Wainwright analyst Joseph Pantginis raised the price target on Curis (NASDAQ: CRIS) to $43.00 (from $17.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Curis+%28CRIS%29+PT+Raised+to+%2443+at+H.C.+Wainwright/26810687.html Fri, 24 Jul 2026 07:31:28 -0400 CRIS http://www.streetinsider.com/Corporate+News/Curis+reports+updated+emavusertib+trial+data+in+PCNSL+and+CLL/26798062.html <p>Curis, Inc. (NASDAQ: CRIS) released updated clinical data from its TakeAim Lymphoma registrational study in Primary CNS Lymphoma (PCNSL) and provided revised enrollment guidance for its Phase 2 TakeAim CLL study in Chronic Lymphocytic Leukemia, according to a company statement dated July 22, 2026.</p><p>In the PCNSL study, data as of July 1, 2026 showed that among evaluable BTKi-naïve patients, 5 of 5 achieved an objective response rate (ORR) of 100%, compared with 71% ORR reported in previous data from May 2025. Among BTKi-experienced evaluable patients, 10 of 30 achieved a 33% ORR, compared with 27% ORR previously reported across all http://www.streetinsider.com/Corporate+News/Curis+reports+updated+emavusertib+trial+data+in+PCNSL+and+CLL/26798062.html Wed, 22 Jul 2026 07:01:26 -0400 CRIS http://www.streetinsider.com/FDA/Curis+reports+updated+emavusertib+trial+data+in+PCNSL+and+CLL/26798062.html <p>Curis, Inc. (NASDAQ: CRIS) released updated clinical data from its TakeAim Lymphoma registrational study in Primary CNS Lymphoma (PCNSL) and provided revised enrollment guidance for its Phase 2 TakeAim CLL study in Chronic Lymphocytic Leukemia, according to a company statement dated July 22, 2026.</p><p>In the PCNSL study, data as of July 1, 2026 showed that among evaluable BTKi-naïve patients, 5 of 5 achieved an objective response rate (ORR) of 100%, compared with 71% ORR reported in previous data from May 2025. Among BTKi-experienced evaluable patients, 10 of 30 achieved a 33% ORR, compared with 27% ORR previously reported across all http://www.streetinsider.com/FDA/Curis+reports+updated+emavusertib+trial+data+in+PCNSL+and+CLL/26798062.html Wed, 22 Jul 2026 07:01:26 -0400 CRIS http://www.streetinsider.com/Press+Releases/Curis+Announces+Positive+Emavusertib+Update/26798007.html <div class="xn-content"> <p class="prntac"><i>Updated Clinical Data in PCNSL</i></p><p class="prntac"><i>Increased Guidance on Year-End Data in CLL</i></p><p class="prntac"><i>Company to Host Webcast at <chron>8:30 a.m. ET</chron></i></p><p><span class="legendSpanClass"><location value="LU/us.ma.lexton" idsrc="xmltag.org" >LEXINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CRIS" idsrc="xmltag.org" >Curis, Inc.</span> (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that it will host a webcast on <chron>Wednesday, July 22</chron> at <chron>8:30 a.m. ET</chron> to discuss positive updated clinical data in the TakeAim Lymphoma study, its ongoing registrational study in Primary CNS Lymphoma (PCNSL), and provide updated guidance on http://www.streetinsider.com/Press+Releases/Curis+Announces+Positive+Emavusertib+Update/26798007.html Wed, 22 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 CRIS O.00176055 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Curis+Announces+Positive+Emavusertib+Update/26798007.html <div class="xn-content"> <p class="prntac"><i>Updated Clinical Data in PCNSL</i></p><p class="prntac"><i>Increased Guidance on Year-End Data in CLL</i></p><p class="prntac"><i>Company to Host Webcast at <chron>8:30 a.m. ET</chron></i></p><p><span class="legendSpanClass"><location value="LU/us.ma.lexton" idsrc="xmltag.org" >LEXINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CRIS" idsrc="xmltag.org" >Curis, Inc.</span> (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that it will host a webcast on <chron>Wednesday, July 22</chron> at <chron>8:30 a.m. ET</chron> to discuss positive updated clinical data in the TakeAim Lymphoma study, its ongoing registrational study in Primary CNS Lymphoma (PCNSL), and provide updated guidance on http://www.streetinsider.com/Press+Releases/Curis+Announces+Positive+Emavusertib+Update/26798007.html Wed, 22 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 CRIS O.00176055 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Curis+Announces+Positive+Emavusertib+Update/26798007.html <div class="xn-content"> <p class="prntac"><i>Updated Clinical Data in PCNSL</i></p><p class="prntac"><i>Increased Guidance on Year-End Data in CLL</i></p><p class="prntac"><i>Company to Host Webcast at <chron>8:30 a.m. ET</chron></i></p><p><span class="legendSpanClass"><location value="LU/us.ma.lexton" idsrc="xmltag.org" >LEXINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CRIS" idsrc="xmltag.org" >Curis, Inc.</span> (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that it will host a webcast on <chron>Wednesday, July 22</chron> at <chron>8:30 a.m. ET</chron> to discuss positive updated clinical data in the TakeAim Lymphoma study, its ongoing registrational study in Primary CNS Lymphoma (PCNSL), and provide updated guidance on http://www.streetinsider.com/Press+Releases/Curis+Announces+Positive+Emavusertib+Update/26798007.html Wed, 22 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 CRIS O.00176055 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Curis+Announces+Positive+Emavusertib+Update/26798007.html <div class="xn-content"> <p class="prntac"><i>Updated Clinical Data in PCNSL</i></p><p class="prntac"><i>Increased Guidance on Year-End Data in CLL</i></p><p class="prntac"><i>Company to Host Webcast at <chron>8:30 a.m. ET</chron></i></p><p><span class="legendSpanClass"><location value="LU/us.ma.lexton" idsrc="xmltag.org" >LEXINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CRIS" idsrc="xmltag.org" >Curis, Inc.</span> (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that it will host a webcast on <chron>Wednesday, July 22</chron> at <chron>8:30 a.m. ET</chron> to discuss positive updated clinical data in the TakeAim Lymphoma study, its ongoing registrational study in Primary CNS Lymphoma (PCNSL), and provide updated guidance on http://www.streetinsider.com/Press+Releases/Curis+Announces+Positive+Emavusertib+Update/26798007.html Wed, 22 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 CRIS O.00176055 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Curis+Announces+Positive+Emavusertib+Update/26798007.html <div class="xn-content"> <p class="prntac"><i>Updated Clinical Data in PCNSL</i></p><p class="prntac"><i>Increased Guidance on Year-End Data in CLL</i></p><p class="prntac"><i>Company to Host Webcast at <chron>8:30 a.m. ET</chron></i></p><p><span class="legendSpanClass"><location value="LU/us.ma.lexton" idsrc="xmltag.org" >LEXINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CRIS" idsrc="xmltag.org" >Curis, Inc.</span> (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that it will host a webcast on <chron>Wednesday, July 22</chron> at <chron>8:30 a.m. ET</chron> to discuss positive updated clinical data in the TakeAim Lymphoma study, its ongoing registrational study in Primary CNS Lymphoma (PCNSL), and provide updated guidance on http://www.streetinsider.com/Press+Releases/Curis+Announces+Positive+Emavusertib+Update/26798007.html Wed, 22 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 CRIS O.00176055 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Curis+Announces+Positive+Emavusertib+Update/26798007.html <div class="xn-content"> <p class="prntac"><i>Updated Clinical Data in PCNSL</i></p><p class="prntac"><i>Increased Guidance on Year-End Data in CLL</i></p><p class="prntac"><i>Company to Host Webcast at <chron>8:30 a.m. ET</chron></i></p><p><span class="legendSpanClass"><location value="LU/us.ma.lexton" idsrc="xmltag.org" >LEXINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CRIS" idsrc="xmltag.org" >Curis, Inc.</span> (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that it will host a webcast on <chron>Wednesday, July 22</chron> at <chron>8:30 a.m. ET</chron> to discuss positive updated clinical data in the TakeAim Lymphoma study, its ongoing registrational study in Primary CNS Lymphoma (PCNSL), and provide updated guidance on http://www.streetinsider.com/Press+Releases/Curis+Announces+Positive+Emavusertib+Update/26798007.html Wed, 22 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 CRIS O.00176055 O.20026344 O.22422661 http://www.streetinsider.com/PRNewswire/Curis+Announces+Positive+Emavusertib+Update/26798007.html <div class="xn-content"> <p class="prntac"><i>Updated Clinical Data in PCNSL</i></p><p class="prntac"><i>Increased Guidance on Year-End Data in CLL</i></p><p class="prntac"><i>Company to Host Webcast at <chron>8:30 a.m. ET</chron></i></p><p><span class="legendSpanClass"><location value="LU/us.ma.lexton" idsrc="xmltag.org" >LEXINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CRIS" idsrc="xmltag.org" >Curis, Inc.</span> (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that it will host a webcast on <chron>Wednesday, July 22</chron> at <chron>8:30 a.m. ET</chron> to discuss positive updated clinical data in the TakeAim Lymphoma study, its ongoing registrational study in Primary CNS Lymphoma (PCNSL), and provide updated guidance on http://www.streetinsider.com/PRNewswire/Curis+Announces+Positive+Emavusertib+Update/26798007.html Wed, 22 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 CRIS O.00176055 O.20026344 O.22422661 http://www.streetinsider.com/PRNewswire/Curis+Announces+Positive+Emavusertib+Update/26798007.html <div class="xn-content"> <p class="prntac"><i>Updated Clinical Data in PCNSL</i></p><p class="prntac"><i>Increased Guidance on Year-End Data in CLL</i></p><p class="prntac"><i>Company to Host Webcast at <chron>8:30 a.m. ET</chron></i></p><p><span class="legendSpanClass"><location value="LU/us.ma.lexton" idsrc="xmltag.org" >LEXINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CRIS" idsrc="xmltag.org" >Curis, Inc.</span> (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that it will host a webcast on <chron>Wednesday, July 22</chron> at <chron>8:30 a.m. ET</chron> to discuss positive updated clinical data in the TakeAim Lymphoma study, its ongoing registrational study in Primary CNS Lymphoma (PCNSL), and provide updated guidance on http://www.streetinsider.com/PRNewswire/Curis+Announces+Positive+Emavusertib+Update/26798007.html Wed, 22 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 CRIS O.00176055 O.20026344 O.22422661 http://www.streetinsider.com/PRNewswire/Curis+Announces+Positive+Emavusertib+Update/26798007.html <div class="xn-content"> <p class="prntac"><i>Updated Clinical Data in PCNSL</i></p><p class="prntac"><i>Increased Guidance on Year-End Data in CLL</i></p><p class="prntac"><i>Company to Host Webcast at <chron>8:30 a.m. ET</chron></i></p><p><span class="legendSpanClass"><location value="LU/us.ma.lexton" idsrc="xmltag.org" >LEXINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CRIS" idsrc="xmltag.org" >Curis, Inc.</span> (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that it will host a webcast on <chron>Wednesday, July 22</chron> at <chron>8:30 a.m. ET</chron> to discuss positive updated clinical data in the TakeAim Lymphoma study, its ongoing registrational study in Primary CNS Lymphoma (PCNSL), and provide updated guidance on http://www.streetinsider.com/PRNewswire/Curis+Announces+Positive+Emavusertib+Update/26798007.html Wed, 22 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 CRIS O.00176055 O.20026344 O.22422661 http://www.streetinsider.com/PRNewswire/Curis+Announces+Positive+Emavusertib+Update/26798007.html <div class="xn-content"> <p class="prntac"><i>Updated Clinical Data in PCNSL</i></p><p class="prntac"><i>Increased Guidance on Year-End Data in CLL</i></p><p class="prntac"><i>Company to Host Webcast at <chron>8:30 a.m. ET</chron></i></p><p><span class="legendSpanClass"><location value="LU/us.ma.lexton" idsrc="xmltag.org" >LEXINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CRIS" idsrc="xmltag.org" >Curis, Inc.</span> (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that it will host a webcast on <chron>Wednesday, July 22</chron> at <chron>8:30 a.m. ET</chron> to discuss positive updated clinical data in the TakeAim Lymphoma study, its ongoing registrational study in Primary CNS Lymphoma (PCNSL), and provide updated guidance on http://www.streetinsider.com/PRNewswire/Curis+Announces+Positive+Emavusertib+Update/26798007.html Wed, 22 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 CRIS O.00176055 O.20026344 O.22422661 http://www.streetinsider.com/PRNewswire/Curis+Announces+Positive+Emavusertib+Update/26798007.html <div class="xn-content"> <p class="prntac"><i>Updated Clinical Data in PCNSL</i></p><p class="prntac"><i>Increased Guidance on Year-End Data in CLL</i></p><p class="prntac"><i>Company to Host Webcast at <chron>8:30 a.m. ET</chron></i></p><p><span class="legendSpanClass"><location value="LU/us.ma.lexton" idsrc="xmltag.org" >LEXINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CRIS" idsrc="xmltag.org" >Curis, Inc.</span> (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that it will host a webcast on <chron>Wednesday, July 22</chron> at <chron>8:30 a.m. ET</chron> to discuss positive updated clinical data in the TakeAim Lymphoma study, its ongoing registrational study in Primary CNS Lymphoma (PCNSL), and provide updated guidance on http://www.streetinsider.com/PRNewswire/Curis+Announces+Positive+Emavusertib+Update/26798007.html Wed, 22 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 CRIS O.00176055 O.20026344 O.22422661 http://www.streetinsider.com/PRNewswire/Curis+Announces+Positive+Emavusertib+Update/26798007.html <div class="xn-content"> <p class="prntac"><i>Updated Clinical Data in PCNSL</i></p><p class="prntac"><i>Increased Guidance on Year-End Data in CLL</i></p><p class="prntac"><i>Company to Host Webcast at <chron>8:30 a.m. ET</chron></i></p><p><span class="legendSpanClass"><location value="LU/us.ma.lexton" idsrc="xmltag.org" >LEXINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CRIS" idsrc="xmltag.org" >Curis, Inc.</span> (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that it will host a webcast on <chron>Wednesday, July 22</chron> at <chron>8:30 a.m. ET</chron> to discuss positive updated clinical data in the TakeAim Lymphoma study, its ongoing registrational study in Primary CNS Lymphoma (PCNSL), and provide updated guidance on http://www.streetinsider.com/PRNewswire/Curis+Announces+Positive+Emavusertib+Update/26798007.html Wed, 22 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 CRIS O.00176055 O.20026344 O.22422661 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CURIS+INC+++++++++++++++++For%3A+Jul+07++Filed+by%3A+Rubin+Marc/26753340.html si-local-file:///var/storage/secattach/20260709/26753340.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CURIS+INC+++++++++++++++++For%3A+Jul+07++Filed+by%3A+Rubin+Marc/26753340.html Thu, 09 Jul 2026 16:13:00 -0400 CRIS O.00176055 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CURIS+INC+++++++++++++++++For%3A+Jul+07++Filed+by%3A+Rubin+Marc/26753340.html si-local-file:///var/storage/secattach/20260709/26753340.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CURIS+INC+++++++++++++++++For%3A+Jul+07++Filed+by%3A+Rubin+Marc/26753340.html Thu, 09 Jul 2026 16:13:00 -0400 CRIS O.00176055 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CURIS+INC+++++++++++++++++For%3A+Jul+07++Filed+by%3A+GREENACRE+MARTYN+D/26753323.html si-local-file:///var/storage/secattach/20260709/26753323.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CURIS+INC+++++++++++++++++For%3A+Jul+07++Filed+by%3A+GREENACRE+MARTYN+D/26753323.html Thu, 09 Jul 2026 16:12:00 -0400 CRIS O.00176055 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CURIS+INC+++++++++++++++++For%3A+Jul+07++Filed+by%3A+GREENACRE+MARTYN+D/26753323.html si-local-file:///var/storage/secattach/20260709/26753323.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CURIS+INC+++++++++++++++++For%3A+Jul+07++Filed+by%3A+GREENACRE+MARTYN+D/26753323.html Thu, 09 Jul 2026 16:12:00 -0400 CRIS O.00176055 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CURIS+INC+++++++++++++++++For%3A+Jul+07++Filed+by%3A+Hohneker+John/26753326.html si-local-file:///var/storage/secattach/20260709/26753326.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CURIS+INC+++++++++++++++++For%3A+Jul+07++Filed+by%3A+Hohneker+John/26753326.html Thu, 09 Jul 2026 16:12:00 -0400 CRIS O.00176055 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CURIS+INC+++++++++++++++++For%3A+Jul+07++Filed+by%3A+Hohneker+John/26753326.html si-local-file:///var/storage/secattach/20260709/26753326.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CURIS+INC+++++++++++++++++For%3A+Jul+07++Filed+by%3A+Hohneker+John/26753326.html Thu, 09 Jul 2026 16:12:00 -0400 CRIS O.00176055 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CURIS+INC+++++++++++++++++For%3A+Jul+07++Filed+by%3A+KAITIN+KENNETH+I/26753331.html si-local-file:///var/storage/secattach/20260709/26753331.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CURIS+INC+++++++++++++++++For%3A+Jul+07++Filed+by%3A+KAITIN+KENNETH+I/26753331.html Thu, 09 Jul 2026 16:12:00 -0400 CRIS O.00176055 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CURIS+INC+++++++++++++++++For%3A+Jul+07++Filed+by%3A+KAITIN+KENNETH+I/26753331.html si-local-file:///var/storage/secattach/20260709/26753331.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CURIS+INC+++++++++++++++++For%3A+Jul+07++Filed+by%3A+KAITIN+KENNETH+I/26753331.html Thu, 09 Jul 2026 16:12:00 -0400 CRIS O.00176055 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CURIS+INC+++++++++++++++++For%3A+Jul+07++Filed+by%3A+Duvall+Diantha/26753317.html si-local-file:///var/storage/secattach/20260709/26753317.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CURIS+INC+++++++++++++++++For%3A+Jul+07++Filed+by%3A+Duvall+Diantha/26753317.html Thu, 09 Jul 2026 16:11:00 -0400 CRIS O.00176055 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CURIS+INC+++++++++++++++++For%3A+Jul+07++Filed+by%3A+Duvall+Diantha/26753317.html si-local-file:///var/storage/secattach/20260709/26753317.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CURIS+INC+++++++++++++++++For%3A+Jul+07++Filed+by%3A+Duvall+Diantha/26753317.html Thu, 09 Jul 2026 16:11:00 -0400 CRIS O.00176055